

Anticoagulation for Stroke Prevention in Non-Valvular Atrial Fibrillation: Sheffield joint primary and secondary care guidance

Version 3.3 October 2025

Version 3

Approved by: STHFT MMTC: 29th July 2023

NHS SYICB Sheffield APG: 20th July 2023

Review date: July 2026

Version 3.3

Amended by: Hilde Storkes, Lead Pharmacist (Formulary, Sheffield place) SY ICB
Shameila Afsar-Baig, Senior Pharmacist (Strategy and Delivery, Sheffield place) SY ICB
Becs Walsh, Lead Pharmacist for Anticoagulation and Thrombosis Prevention, STHFT

Approved by: Sheffield Area Prescribing Group

Date: October 2025

[Version history](#)

Authors version 3:

Hester Smail Lead Cardiology Pharmacist STH (to end April 2023)	Becs Walsh Lead Pharmacist for Anticoagulation & Thrombosis Prevention STH	Shameila Afsar-Baig Clinical Practice Pharmacist Sheffield place SY ICB	Hilde Storkes Formulary Pharmacist Sheffield place SY ICB
---	--	---	---


Anticoagulation for Stroke Prevention in Non-Valvular Atrial Fibrillation*: Sheffield joint primary and secondary care guidance

This document provides guidance to primary and secondary care prescribers in selecting the most suitable anticoagulant for each patient and conducting appropriate baseline and ongoing monitoring.

*** Non-valvular AF is defined as AF in the absence of a mechanical prosthetic heart valve or moderate to severe mitral stenosis (usually of rheumatic origin)**

Patients with aortic valve disease are therefore included in the scope of this guideline.

Do not wait for the results of any echocardiogram that may, or may not, be requested before anticoagulating. Echocardiogram will not affect the decision to anticoagulate.



Additional information:

[Switching between anticoagulants](#) – page 11

[Dental procedures and other surgery](#) - page 12

[Anticoagulation for AF in patients with chronic liver disease](#) – page 12

Key to symbols used throughout this document:

< = less than > = more than CrCl = calculated creatinine clearance
ULN = upper limit of normal

DOAC = Direct Oral Anticoagulant

Step 1 - Baseline investigations

• Blood tests: U&E, LFT, FBC, clotting screen (results obtained in the previous 6 weeks are acceptable in stable patients. If a patient is being switched to a different anticoagulant, results in the previous 3 months are acceptable; a repeat clotting screen is not required).	• Height and Weight (recent i.e. within last 12 months or more recently if suspected weight loss/gain)	• Blood pressure	• Renal function; use calculated creatinine clearance (CrCl) to estimate renal function for DOAC dosing
--	---	---	--

Calculated creatinine clearance (Cockcroft-Gault):

$$\text{Calculated CrCl} = \frac{(140 - \text{age} \dots\dots) \times \text{weight (kg)} \dots\dots}{\text{Serum Creatinine (micromol/L)} \dots\dots} \times \begin{matrix} 1.04 \text{ (female)} \\ 1.23 \text{ (male)} \end{matrix} = \dots\dots \text{ (mL/min)}$$

For secondary care use ONLY: web-based CrCl calculator, see <https://www.mdcalc.com/creatinine-clearance-cockcroft-gault-equation> (MDcalc takes no liability for using this tool, use with own clinical judgement).

For Primary care there is a Cockcroft-Gault calculator on the clinical systems. Also see [guideline for calculating renal function](#), which includes guidance on interface issues where the dose of DOAC determined in secondary care may differ from that calculated in primary care.

Step 2 – Assessment of stroke and bleeding risks

Calculate CHA₂DS₂VASc score and stroke risk Consider anticoagulation in men with a score of 1
Offer anticoagulation to all patients with score ≥ 2

CHA ₂ DS ₂ VASc criteria (treated or untreated conditions)	Points if present	CHA ₂ DS ₂ VASc score	Annual stroke risk %	5 year risk of thromboembolism % (hospitalisation or death due to ischaemic stroke, peripheral artery embolism, or pulmonary embolism)
Congestive heart failure	1	0	0.0	3.45
Hypertension	1	1	1.3	7.55
Age 75 years or older	2	2	2.2	15.05
Diabetes mellitus	1	3	3.2	22.05
Prior Stroke or TIA	2	4	4.0	33.45
Vascular disease	1	5	6.7	52.1
Age 65-74 years	1	6	9.8	64.25
Sex = female*	1	7	9.6	69.6
TOTAL SCORE (max 9)		8	6.7	70.35
		9	15.2	80.4

*Female sex alone does not confer an additional stroke risk, but risk factors present in females confer additional stroke risk compared with males.

Use ORBIT score to identify and assess bleeding risk**

Orbit criteria	Points if present
Age >74 years	1
Haemoglobin <13g/dL male or <12g/dL female OR Haematocrit <40% male or <36% female	2
Bleeding history	2
eGFR <60ml/min/1.73m ²	1
Treatment with antiplatelet agents	1
TOTAL SCORE (maximum 7)	


ORBIT score	0-2	3	4-7
Annual bleed risk	Low risk 2.4 bleeds per 100 patient-years	Medium risk 4.7 bleeds per 100 patient-years	High risk 8.1 bleeds per 100 patient-years

see [step 3](#) (next page) for guidance on stopping/continuing antiplatelets with anticoagulation

**ORBIT is recommended by NICE as it has a higher accuracy than other bleeding risk tools

Offer monitoring and support to modify risk factors for bleeding, such as uncontrolled hypertension, concurrent medication, harmful alcohol consumption.

Step 3 – Establish which anticoagulants would be appropriate



Antiplatelets

Stable CHD without previous PCI: stop antiplatelets once patient is anticoagulated (i.e. on DOAC or warfarin with INR >2.0).

If previous PCI, or cardiac infarct <12 months ago: seek advice from supervising cardiologist. If greater than 12 months, continue on oral anticoagulant alone.

Carotid stent or peripheral angioplasty/stent: stop antiplatelets if stenting was >6 weeks ago. Specialists may occasionally recommend longer term antiplatelet therapy to be added to anticoagulation. If in doubt, seek advice from vascular radiologist.

Dual antiplatelet therapy may be continued in addition to anticoagulation in certain circumstances (e.g. low bleed risk, or high stroke risk). This will be a specialist decision and should be clearly documented. *If dual antiplatelet therapy is indicated:* a DOAC should be used in preference to warfarin for anticoagulation.

Existing anticoagulation therapy: Patients with ACS needing an antiplatelet and an anticoagulant should be retained on the DOAC as recommended by the consultant cardiologist and not be switched to an alternative.

CLICK [HERE](#) TO RETURN TO PAGE 1

Drug interactions

The information provided below is based on information available at the time of writing and local recommendations. Refer to BNF, SPC and STH Medicines Information/ Sheffield place Medicines Optimisation Team for further information.

	No current data available	✓	Combination appears to be safe	X	Combination has been proven to be clinically unsafe
--	---------------------------	---	--------------------------------	---	---

Caution	Combination is known to / may alter plasma concentration levels. Approach with care and take into account other factors affecting plasma concentration e.g. renal impairment, other concomitant interacting drugs etc. Dose adjustments may be needed.
---------	--

	Edoxaban	Rivaroxaban	Apixaban	Dabigatran
Azole antifungals:				
Posaconazole	✓	X	X	may increase plasma levels of dabigatran, monitor for signs of bleeding
Voriconazole	✓	X	X	may increase plasma levels of dabigatran, monitor for signs of bleeding
Ketoconazole (oral)	reduce edoxaban dose to 30mg if prescribed concurrently	X	X	X
Fluconazole	✓	✓	✓	may increase plasma levels of dabigatran, monitor for signs of bleeding
Anti-arrhythmics:				
Dronedarone	reduce edoxaban dose to 30mg if prescribed concurrently	X	may increase plasma levels of apixaban. Monitor for signs of bleeding	X
Amiodarone	may increase plasma levels of edoxaban. Monitor for signs of bleeding	may increase plasma levels of rivaroxaban. Monitor for signs of bleeding	may increase plasma levels of apixaban. Monitor for signs of bleeding	may increase plasma levels of dabigatran, adjust dose depending on indication & renal function, monitor for signs of bleeding
Quinidine	may increase plasma levels of edoxaban. Monitor for signs of bleeding	No data currently available	may increase plasma levels of apixaban. Monitor for signs of bleeding	may increase plasma levels of dabigatran, monitor for signs of bleeding. Stop dabigatran if bleeding occurs
Verapamil	may increase plasma levels of edoxaban. Monitor for signs of bleeding	✓	✓	may increase plasma levels of dabigatran (maximum dabigatran dose 110mg BD)
Other drugs:				
Clarithromycin	may increase plasma levels of edoxaban. Monitor for signs of bleeding	may increase plasma levels of rivaroxaban. Monitor for signs of bleeding	may increase plasma levels of apixaban. Monitor for signs of bleeding	may increase plasma levels of dabigatran, monitor for signs of bleeding. Stop dabigatran if bleeding occurs
Erythromycin	reduce edoxaban dose to 30mg during course of erythromycin, if prescribed concurrently. Monitor for signs of bleeding	may increase plasma levels of rivaroxaban	may increase plasma levels of apixaban. Monitor for signs of bleeding	may increase plasma levels of dabigatran, monitor for signs of bleeding. Stop dabigatran if bleeding occurs

Additional notes:

The following drugs are contraindicated with DOACs, and warfarin should be used for anticoagulation:

HIV protease inhibitors
Itraconazole
Rifampicin

The following drugs are either contraindicated or not recommended with apixaban, rivaroxaban and dabigatran. They may reduce the plasma concentrations of edoxaban and should be used with caution on an individual patient basis:

St. John's Wort
Carbamazepine
Phenytoin
Phenobarbital
Primidone

Amiodarone and warfarin

Significant dose adjustments required when amiodarone is started - refer to STH guidelines/ primary care Anticoagulant monitoring service SOP.

Rifampicin and warfarin

Substantial dose adjustments required when rifampicin is started or stopped - refer to STH guidelines / primary care Anticoagulant monitoring SOP

DOACs/Warfarin interact with SSRIs/SNRIs

Increased risk of bleeding when prescribed concurrently, consider the use of PPI.

Anticoagulation for stroke prevention in non-valvular AF: Sheffield joint primary and secondary care guidance.

Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield place SYICB version 3.3 October 2025

	Edoxaban	Rivaroxaban	Apixaban	Dabigatran		Additional notes
Ciclosporin	reduce edoxaban dose to 30mg if prescribed concurrently	may increase plasma levels of rivaroxaban. Monitor for signs of bleeding	may increase plasma levels of apixaban. Monitor for signs of bleeding	X		Warfarin has a number of drug/food interactions. Please refer to the BNF, SPC and primary care Anticoagulant monitoring service SOP (Appendix 4) *Seek specialist advice if initiating DOAC in a patient established on tacrolimus.
Tacrolimus*	caution- may increase plasma levels of edoxaban	✓	✓	X		
Ticagrelor (also note general antiplatelet guidance)	✓	✓	concurrent prescribing should only be on Cardiologist advice	may increase plasma levels of dabigatran, monitor for signs of bleeding. Stop dabigatran if bleeding occurs		

CLICK [HERE](#) TO RETURN TO PAGE 1

Considerations in choosing an anticoagulant (see pages 3 & 4 before this step)

These are divided into clinical considerations and practical considerations.

The ● symbolises indicate the drug(s) that are more appropriate due to good trial evidence or having a significant amount of experience with their use.

Clinical considerations	Edoxaban	Rivaroxaban	Apixaban	Dabigatran 110mg	Dabigatran 150mg	Warfarin
High risk of bleeding (ORBIT ≥4) ensure modifiable risk factors for bleeding are addressed: blood pressure control, drugs, alcohol			●	●		
History of GI bleed			●	●		●
Risk of dyspepsia or upper GI upset or disorder ¹	●	●	●			●
Low/moderate bleeding risk (ORBIT≤3) and age < 80 years	●	●	●		●	●
High renal clearance - CrCl >95ml/min		●	●			●
Renal impairment – CrCl <15ml/min						●
Body weight <45kg						●
Body weight 45-120kg with a BMI<40kg/m ²	●	●	●			●
Body weight 121-150kg with a BMI<40kg/m ²		●	●			●
Body weight >150kg or BMI>40kg/m ²						●
Liver impairment – AST/ALT >2 x ULN						●
Practical considerations	Edoxaban	Rivaroxaban	Apixaban	Dabigatran 110mg	Dabigatran 150mg	Warfarin
Once a day formulation preferred	●	●				●
Requirement for a compliance aid ² (weekly monitored dosage systems filled by pharmacy, or weekly tablet organiser filled by patient, e.g. Nomad, Dossette, etc)	●	●	●			●
Swallowing difficulties or requiring administration through gastric tubes ³	●	●	●			●
Erratic meal pattern ⁴	●		●			●
Concerns with medication adherence / concordance ⁵						●
Availability of a reversal agent ⁶		●	●	●	●	●

1 - Consider prescribing PPI, but note that PPIs *may* reduce absorption of dabigatran

2 - Compliance aids: **Dabigatran** must be kept in the original packaging with desiccant, therefore is not suitable for use in compliances aids or weekly pill organisers. **Warfarin** may be suitable in a compliance aid following appropriate risk assessment and the existence of a management plan to manage dosage changes. Apixaban, rivaroxaban and edoxaban have no special storage conditions.

3 - Swallowing difficulties and gastric tubes:

- **Edoxaban, rivaroxaban, and apixaban** are licensed to be crushed and mixed with water or apple puree immediately prior to oral administration. They may be given through a nasogastric or PEG tube. The tablet should be crushed and administered in a small amount of water via a gastric tube after which it should be flushed with water. None are suitable for administration through feeding tubes which do not terminate in the stomach e.g. NJ, PEJ and PEGJ tubes. If being fed with a bolus PEG/NG feeding regime, rivaroxaban should be administered whilst the feed is in progress.
- **Warfarin** 1mg/ml suspension (available from Rosemont) can be used in swallowing difficulties and can be administered through an enteral tube after diluting the suspension with the same volume of distilled water. Crushing warfarin tablets is off-licence.
- **Dabigatran** must be administered in its original form. The capsules must not be opened or chewed/crushed.

4 - DOACs currently have no known food or alcohol interactions. Rivaroxaban **must** be taken with food.

5 - Patients with poor concordance may be at a greater risk of thromboembolic complications with DOACs as the shorter half-lives of these agents compared to warfarin will potentially result in more time without any degree of anticoagulation, if a dose is missed.

6 - At the time of writing, licensed commercially available reversal agents are available for dabigatran, apixaban & rivaroxaban. Vitamin K will fully reverse anticoagulation with warfarin but *will not* reverse the DOACs.

CLICK [HERE](#) TO RETURN TO PAGE 1

Step 4 – Discuss options with patient, and provide patient information

For patients who lack capacity, a decision should be taken in the patients “best interests” in line with GMC guidance.

The discussion should cover:

- Stroke and bleeding risk
- Suitable anticoagulation options and the differences between them
 - Dosing
 - Monitoring
 - The effects of other medications, food and alcohol
- How to use anticoagulants
 - The correct dose
 - What to do in case of a missed dose
- Duration of anticoagulation treatment
- Possible side effects and what to do if these occur

Provide written information covering:

- How anticoagulation may affect dental treatment
- How anticoagulants may affect activities such as sports and travel
- When and how to seek medical help
- Women of childbearing potential who are taking anticoagulants should be advised to take contraceptive precautions and contact their GP urgently if they think they may be pregnant.
- Rivaroxaban must be taken with food to ensure full absorption
- Dabigatran should be taken with food to reduce the likelihood of heartburn/indigestion

Patient information and resources:

Drug information booklets:

- Apixaban – (generic and brand Eliquis®) PIL and alert cards can be downloaded and printed from the [eMC](#); see Patient Information (PIL) and Risk materials tabs respectively.
- Rivaroxaban – (generic and brand Xarelto®) PIL and alert cards can be downloaded and printed from the [eMC](#); see Patient Information (PIL) and Risk materials tabs respectively.
- Edoxaban – Lixiana® [PIL](#) and [alert cards](#) can be downloaded and printed from the links or ordered from Daiichi Sankyo UK (telephone 0800 198 5000).
- Dabigatran – Pradaxa® [PIL](#) and [alert card](#) can be downloaded and printed from the links. Copies of the patient booklet can be ordered by HCP only from distribution.bra@boehringer-ingelheim.com
- A warfarin anticoagulant record (yellow book) can be ordered via [Primary Care Support England \(PCSE\)](#)
- A generic DOAC information booklet can be ordered via [Primary Care Support England \(PCSE\)](#)

CLICK [HERE](#) TO RETURN TO PAGE 1

Step 5 – Prescribe the selected anticoagulant

Apixaban generic – joint best value overall and best value twice daily DOAC*	
5mg twice a day (usual dose)	2.5mg twice a day Reduced dose if: • CrCl 15-29ml/min OR If two of the following apply: • Age ≥ 80 yrs • Body weight ≤ 60kg • serum creatinine >133 micromol/L

Rivaroxaban generic – joint best value overall and best value once daily DOAC*	
20mg once a day (usual dose)	15mg once a day Reduced dose if CrCl 15-49ml/min

Edoxaban	
60mg once a day (usual dose)	30mg once a day Reduced dose if one or more of the following apply: • CrCl 15-50ml/min • Body weight ≤ 60kg • Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole <i>From trial data, a trend towards decreasing efficacy with increasing creatinine clearance was observed for edoxaban compared with well-managed warfarin. Therefore, edoxaban should only be used in patients with a high creatinine clearance (>95ml/min) after a careful evaluation of the individual thromboembolic and bleeding risk.</i>

Dabigatran	
150mg twice a day (usual dose)	110mg twice a day Reduced dose if any of the following apply: • Age ≥80 years • Concomitant verapamil Reduced dose should be considered in the following, based on individual assessment of thromboembolic risk and risk of bleeding: • Patients between 75-80 years • Patients with moderate renal impairment (CrCl 30-50ml/min) • Patients with gastritis, esophagitis or gastroesophageal reflux • Other patients at increased risk of bleeding (e.g., ORBIT >3, history of GI bleed, etc.). Note that dabigatran is not licensed with CrCl <30ml/min

*[NHS England Operational note](#) (16 Jan, updated 6 Sept 2024). Clinicians should use the best value DOAC that is clinically appropriate for the patient.

Warfarin	
Primary care • If the practice is contracted to provide Level 5 anticoagulation, <i>and</i> the patient is suitable, start Slow Start warfarin. • Otherwise, refer to STH Anticoagulation Clinic for warfarin initiation. The referral letter/form must be signed by a prescriber, and needs to include: ○ Indication for anticoagulation ○ Target INR range (generally 2.0 – 3.0 for stroke prevention in AF) ○ Duration of anticoagulation (generally long term for AF) ○ A full list of current medication ○ Instructions regarding whether antiplatelets are to stop or continue once INR is >2.0 (see page 3 for guidance)	Secondary care Start warfarin following the warfarin loading protocol on the STH Warfarin Prescription and Monitoring Chart . On discharge from hospital, refer patient to STH Anticoagulation Clinic via ICE.
The Anticoagulation Clinic will provide the patient with an initial supply of warfarin 1mg and 3mg tablets, and GPs will be required to add warfarin on to the repeat prescription thereafter. In certain circumstances it may be appropriate to only prescribe the 1mg tablets (e.g., patients on daily doses of less than 3mg, visual impairment, or lack of confidence handling a combination of strengths).	

CLICK [HERE](#) TO RETURN TO PAGE 1

Step 6 - Ongoing monitoring of anticoagulation

	All DOACs				Warfarin
Early monitoring until patient stabilised	Monitoring/follow-up to be undertaken by GP. - No routine anticoagulation monitoring is needed. - Ideally assess patient after 1 month initially and at least every 3 months thereafter to: - Assess compliance and reinforce advice regarding regular dosing schedule. - Enquire about adverse effects such as bleeding. - Assess for the presence of thromboembolic events. - Enquire about other medicines, including OTC medicines.				INR monitoring as per STH Anticoagulation Clinic guidelines or Sheffield primary care anticoagulation SOP . After 6 months Review anticoagulation control (see below for unstable criteria)
Long term monitoring	- U&E, LFT and FBC at least annually. - Consider monitoring more frequently than annually in the following patients at increased risk of bleeding: - declining renal function (calculated CrCl <60ml/min) see below; - frail or increasing age >75 years: use clinical judgement, for example, EHRA expert opinion suggests monitoring every 4 months; - intercurrent illness; - concomitant medicines that may impact on renal or liver function; - hepatic function changes.				Annually - LFTs - U&E - FBC - Review anticoagulation control (see below for unstable criteria)
National guidance as per NICE CKS and SPS	Edoxaban	Rivaroxaban	Apixaban	Dabigatran	
	U&E: - CrCl >60ml/min – annually - CrCl <60ml/min- the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.	U&E: - CrCl >60ml/min – annually - CrCl <60ml/min- the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.	U&E: - CrCl >60ml/min – annually - CrCl <60ml/min- the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.	U&E: - Patient <75 years and CrCl >60ml/min – annually - Age >75 years or fragile – every 4 month - CrCl 30 - 60ml/min - the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.	
Blue font- Alternative local guidance for a pragmatic approach if above not suitable for	OR U&E: - CrCl >60ml/min – annually - CrCl 36 – 60ml/min – every 6 months - CrCl 15 – 35ml/min – every 3 months	OR U&E: - CrCl >60ml/min – annually - CrCl 36 – 60ml/min – every 6 months - CrCl 15 – 35ml/min – every 3 months	OR U&E: - CrCl >60ml/min – annually - CrCl 36 – 60ml/min – every 6 months - CrCl 15 – 35ml/min – every 3 months	OR U&E: - Patient <75 years and CrCl >60ml/min – annually - Age >75 years or fragile – every 4 months - CrCl 36 – 60ml/min – every 6 months	

	All DOACs				Warfarin
patient and/or practice.	CrCl <15ml/min- do not use	CrCl <15ml/min- do not use	CrCl <15ml/min- do not use	• CrCl 30 – 35ml/min – every 3 months CrCl <30ml/min – do not use	
Action required if abnormal results	Edoxaban Renal function: • If CrCl 15-50ml/min, reduce dose of edoxaban to 30mg OD • If CrCl <15ml/min, stop edoxaban and switch to warfarin.	Rivaroxaban Renal function: • If CrCl 15-49ml/min, reduce dose of rivaroxaban to 15mg OD • If CrCl <15ml/min, stop rivaroxaban and switch to warfarin.	Apixaban Renal function: • Reduce dose to 2.5mg BD if indicated by combination of age, weight and serum creatinine • Reduce dose to 2.5mg BD if CrCl 15-29ml/min • If CrCl <15ml/min, stop apixaban and switch to warfarin.	Dabigatran Renal function: • If CrCl 30-50ml/min, reduce dose of dabigatran to 110mg BD • If CrCl <30ml/min, stop dabigatran and switch to warfarin.	Unstable anticoagulation: Review adherence to medication. Review diet, alcohol intake and other lifestyle factors. Switch to DOAC if appropriate (see considerations).
	Liver function: Elevated liver enzymes (ALT/AST >2 x ULN) or total bilirubin ≥1.5 x ULN: stop edoxaban & switch to warfarin (also see page 12).	Liver function: Elevated liver enzymes (ALT/AST >2 x ULN), or Child-Pugh score B or C: stop rivaroxaban & switch to warfarin (also see page 12).	Liver function: Elevated liver enzymes (ALT/AST >2 x ULN) or total bilirubin ≥1.5 x ULN: stop apixaban & switch to warfarin (also see page 12).	Liver function: Elevated liver enzymes (ALT/AST >2 x ULN): stop dabigatran & switch to warfarin (also see page 12).	<u>UNSTABLE ANTICOAGULATION – criteria</u> Any one of: • 2 INRs >5 in the last 6 months • 1 INR >8 in the last 6 months • 2 INRs <1.5 in the last 6 months (outwith planned interruptions) • Time in therapeutic range <65%
	Full blood count: An unexplained fall in haemoglobin and/or haematocrit may suggest that occult bleeding is occurring and may require further investigations.	Full blood count: An unexplained fall in haemoglobin and/or haematocrit may suggest that occult bleeding is occurring and may require further investigations.	Full blood count: An unexplained fall in haemoglobin and/or haematocrit may suggest that occult bleeding is occurring and may require further investigations.	Full blood count: An unexplained fall in haemoglobin and/or haematocrit may suggest that occult bleeding is occurring and may require further investigations.	

Switching between anticoagulants

Warfarin to DOAC	DOACs to warfarin
The SmPCs for individual DOACs recommend different INR thresholds for starting DOACs after stopping warfarin. The EHRA 2021 gives pragmatic guidance and recommends that the INR should be <2.5 when the DOAC is started. • If INR <2 commence DOAC the same day • If INR between 2 and 2.5 commence DOAC the next day ideally (or the same day) • If INR between 2.5 and 3 withhold warfarin for 24-72 hours, re-check INR and then initiate DOAC	INRs taken during the switch must be taken using venous samples. The results of Coaguchek® and other point-of-care INR testing will be erroneously affected by the presence of DOAC. Refer patient to STH Anticoagulation Clinic to initiate warfarin
	Edoxaban to warfarin • Start warfarin following an approved loading protocol (NB Slow Start is not suitable). • Patients taking a 60mg dose of edoxaban should be switched to 30mg. Patients taking a 30mg dose should be switched to 15mg. • INR must be taken using a venous sample, at least 24 hours after the last dose of edoxaban (and immediately prior to the next dose of edoxaban). Continue edoxaban until INR ≥ 2.0
	Rivaroxaban to warfarin • Start warfarin following an approved loading protocol (NB Slow Start is not suitable). • Continue taking rivaroxaban. • INR must be taken using a venous sample, at least 24 hours after the last dose of rivaroxaban (and immediately prior to the next dose of rivaroxaban). • Continue rivaroxaban until INR ≥ 2.0
	Dabigatran to warfarin* • Start warfarin following an approved loading protocol (NB Slow Start is not suitable). • Continue taking dabigatran. • INR must be taken using a venous sample, at least 12 hours after the last dose of dabigatran (and immediately prior to the next dose of dabigatran). • Continue dabigatran until INR ≥ 2.0 • INRs checked whilst on dabigatran or within 3 days of stopping dabigatran must be taken using a venous sample. The result should be interpreted with caution as dabigatran can increase INR. *The above advice is derived from pragmatic interpretation of information presented in the SPC for dabigatran.
	Apixaban to warfarin • Start warfarin following an approved loading protocol (NB Slow Start is not suitable). • Continue taking apixaban. • INR must be taken using a venous sample, at least 12 hours after the last dose of apixaban (and immediately prior to the next dose of apixaban). • Continue apixaban until INR ≥ 2.0

DOAC to DOAC
Start new drug when dose of previous drug would have been due. Patients must not be on more than one DOAC at once.
Parenteral anticoagulant (e.g. dalteparin, fondaparinux) to DOAC DOAC to parenteral anticoagulant
Start new drug when dose of previous drug would have been due. Patients must not be on more than one anticoagulant at once. For management during surgical procedures, see STH guideline “Bridging anticoagulation: the peri-procedural management of patients on oral anticoagulants (excluding neurosurgery)”
Parenteral anticoagulant to warfarin
Follow STH warfarin guidelines. NB: This would not normally be done in primary care.

CLICK [HERE](#) TO RETURN TO PAGE 1

Dental procedures and other surgery

Dental Procedures

Please refer to the [Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs](#), which has been published by the Scottish Dental Clinical Effectiveness Programme (SDCEP). The British Dental Association (BDA) advises that it is intended for use throughout the UK and aims to provide clear and practical advice for the dental team, including on assessment of bleeding risk and decision making for treatment planning.

In addition to the full guidance, resources include a quick reference guide and a range of patient leaflets.

- [Full guidance](#) and [Quick Reference Guide](#)
- Patient information leaflet: [Anticoagulant or Antiplatelet Medication and Your Dental Treatment](#)
- Patient information leaflet: [Post-Treatment Advice for Dental Patients](#)
- Pre-treatment instructions: [Direct Oral Anti-Coagulants](#)
- Pre-treatment instructions: [Warfarin](#)

Non-dental procedures

For non-dental procedures, see STH guideline [“Bridging anticoagulation: the peri-procedural management of patients on oral anticoagulants \(excluding neurosurgery\)”](#)

Anticoagulation for AF in patients with chronic liver disease

The following guidance has been produced by the hepatology team for the benefit of non-specialists.

1 - Is there evidence of current liver decompensation?

- bilirubin >40 micromol/L
- albumin <35 g/L
- prolonged PT or APTT

If any of these features are present, seek specialist advice before commencing anticoagulation



If none of the above are present, proceed to question 2



2 - Is there evidence of cirrhosis?

- liver biopsy
- present or previous ascites
- present or previous varices (on endoscopy or imaging)
- persistently low platelet count
- irregular liver edge or splenomegaly on ultrasound
- Fibro scan (transient elastography) score of >15 KPa (*recommended in NAFLD patients with fibrosis risk in intermediate or high range or in other cases where there is doubt*)

If any of these features are present, need to exclude oesophago-gastric varices or other bleeding sources by gastroscopy before considering anticoagulation



**If none of the above are present – can cautiously commence warfarin anticoagulation for AF.
Seek specialist advice before commencing DOACs (edoxaban, apixaban, rivaroxaban or dabigatran)**

CLICK [HERE](#) TO RETURN TO PAGE 1

References

[NICE guidance NG196](#) - Atrial fibrillation: diagnosis and management. National Institute for Health and Care Excellence, April 2021.

[NICE-CKS Anticoagulation-oral](#), April 2023, last revised March 2025.

Specialist Pharmacy Services. [DOAC monitoring](#). July 2021, last updated September 2025

Guidelines on oral anticoagulation with warfarin – fourth edition. British Committee for Standards in Haematology, 2011

[Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs](#), Dental Clinical Guideline. Scottish Dental Clinical Effectiveness Programme 2nd edition Mar 2022, accessed 21/04/23

Medicines Complete, [Stockleys](#) Drug interactions June 2023. (Subscription required)

Eliquis®: Summary of Product Characteristics (available via <https://www.medicines.org.uk>, accessed April 2023)

Pradaxa®: Summary of Product Characteristics (available via <https://www.medicines.org.uk>, accessed April 2023)

Xarelto®: Summary of Product Characteristics (available via <https://www.medicines.org.uk>, accessed April 2023)

Lixiana®: Summary of Product Characteristics (available via <https://www.medicines.org.uk>, accessed April 2023)

Apixiban generic: Summary of Product Characteristics (available via www.medicines.org.uk, accessed April 2024)

Rivaroxaban generic: Summary of Product Characteristics (available via www.medicines.org.uk, accessed Sept 2024)

Bridging anticoagulation: the peri-procedural management of patients on oral anticoagulants (Sheffield Teaching Hospitals, July 2019)

Speed V, Green B, et al. Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. J Thromb and Haemost (2020) 18(9), 2296-2307.

Savelieva I, Camm J, Practical Considerations for Using Novel Oral Anticoagulants in Patients with Atrial Fibrillation. Clin. Cardiol. 37, 1, 32–47 (2014)

Steffel J, Collins R, et al, The 2021 [EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation](#) EP Europace (2021) 23,1612-1676.

Valgimigli M, Bueno H, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J (2018) 39, 213-254.

Kirchhof P, Benussi S, et al 2016 Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J (2016) 37, 2893–2962.

Olesen JB, Lip GYH, et al, Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124

January CT, Samuel LS, et al, 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary J Am Coll Cardiol. 2014; 64(21):2246-2280

[Anticoagulation monitoring service standard operating procedure](#). NHS Sheffield CCG, October 2021.

Jun M, James MT, etc, The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015; 350:h246

NHS England [Operational note](#) Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs) 16 Jan, updated 6 Sept 2024

Acknowledgements

Secondary care	Primary care
Drs Gary Pratt & Ali Ali, Consultants in Stroke Medicine, STH	Dr Andrew McGinty, GP, Clinical Director elective care and long-term conditions, Chair Sheffield APG Sheffield place SYICB
Drs Nick Kelland & Jonathan Sahu, Consultant Cardiologists and Electrophysiologists, STH	Dr Ben Allen, GP and Clinical Director Primary Care, Sheffield place SYICB
Drs Giorgia Saccullo & Rhona Maclean; Consultant Haematologists, STH	Sarah Bentley, Primary Care Development Nurse, Sheffield place SYICB
Dr Andreas Kyriacou, Consultant Cardiologist, STH	
Drs Amer Al-Joudeh, Dermot Gleeson & Barbara Hoeroldt, Consultant Hepatologists, STH	
Dr William McKane, Consultant Nephrologist, STH	
Dr Doug Turner, Consultant Vascular Radiologist, STH	
Ms Nicola Lax, Arrhythmia Nurse Specialist, STH	
Mr Dario Passeo, Lead Pharmacist for Cardiology, STH	
Ms Samantha Fletcher, Lead Pharmacist for Cardiothoracic Surgery, STH	

Version history

Version 1 developed by Rebecca Hammond, Anticoagulant Pharmacist, STHFT and V-Lin Cheong, Medicines Management Pharmacist, Sheffield CCG on behalf of AF interest group.
Date published May 2015

Version 2 developed by: Jannat Muen, Anticoagulation and Thrombosis Prevention Pharmacist, STH and Shameila Afsar, Medicines Management Pharmacist, Sheffield CCG on behalf of the AF interest group
Date published August 2018

Version 2.1 updated by Shameila Afsar, Clinical Practice Pharmacist, and Hilde Storkes, Formulary Pharmacist, Sheffield CCG in consultation with the AF interest group. Review date extended to August 2023 and links added to the latest anticoagulation guidance issued during COVID-19 pandemic.
Date published August 2020

Version 3 developed by Becs Walsh, Anticoagulation and Thrombosis Prevention Pharmacist, STH, Hester Smail Lead Cardiology Pharmacist, STH (to end April 2023) Shameila Afsar, Clinical Practice Pharmacist, and Hilde Storkes, Formulary Pharmacist, Sheffield place SY ICB.
Date published July 2023

Version 3.1 amended by Becs Walsh, Anticoagulation and Thrombosis Prevention Pharmacist, STH and Hilde Storkes, Formulary Pharmacist, Sheffield place SY ICB following NHS England [Operational note](#) Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs) 16 Jan 2024. Drug interactions section (p4/5) also updated.
Date published July 2024

Version 3.2 amended by Becs Walsh, Anticoagulation and Thrombosis Prevention Pharmacist, STH and Hilde Storkes, Formulary Pharmacist, Sheffield place SY ICB following 6 Sept 2024 update to NHS England [Operational note](#) Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs).
Date published September 2024

Version 3.3 amended by Becs Walsh Anticoagulation and Thrombosis Prevention Pharmacist STH, Hilde Storkes Lead Pharmacist (Formulary, Sheffield place) SY ICB, Shameila Afsar-Baig Senior Pharmacist (Strategy and Delivery, Sheffield place) SY ICB following update to [NICE CKS](#) and [SPS](#) guidance on frequency of monitoring for patients over 75 years or those with frailty.
Date published October 2025

CLICK [HERE](#) TO RETURN TO PAGE 1